Carcinogenic N-nitrosamines were recently found
in the sartan family of drugs and caused many drug recalls. Both of
their detection and quantification are therefore important. Methods
reported for N-nitrosamine quantitation rely on the
use of standards and are just applicable to simple N-nitrosamines. There is an urgent need to quantify N-nitrosamines derived from drugs with a complicated structure that
lack standards. To tackle the issue, this study describes a novel
absolute quantitation strategy for N-nitrosamines
using coulometric mass spectrometry (CMS) without standards. In our
approach, N-nitrosamine is first converted into electrochemically
active hydrazine via zinc reduction under acidic condition and the
resulting hydrazine can then be easily quantified using CMS. To validate
our method, six simple N-nitrosamines, N-nitrosodiethylamine (NDEA), N-nitroso-4-phenylpiperidine
(NPhPIP), N-nitrosodiphenylamine (NDPhA), N-nitrosodibutylamine (NDBA), N-nitrosodipropylamine
(NDPA), and N-nitrosopiperidine (NPIP), were chosen
as test samples, and they all were quantified with excellent measurement
accuracy (quantitation error ≤1.1%). Taking this one step further,
as a demonstration of the method utility, a drug-like N-nitrosamine, (R)-N-(2-(6-chloro-5-methyl-1′-nitroso-2,3-dihydrospiro[indene-1,4′-piperidin]-3-yl)propan-2-yl)acetamide
(VII), was also synthesized and successfully quantified
using our method at 15 ppb level in a complex formulation matrix,
following solvent extraction, N-nitrosamine isolation,
and reductive conversion. Because of the feature of requiring no standards,
CMS provides a simple and powerful approach for N-nitrosamine absolute quantitation and has great potential for analysis
of other drug impurities or metabolites.